GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Ondine Biomedical OBI.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

9.35p

+3.89%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Ondine Biomedical — daily OBI

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Ondine Biomedical on TradingView ↗
Market value
£48.5m
Last close × shares
Volume
303.2k
Shares, 9 Nov 2026

About Ondine Biomedical

Its shares trade on LSE under the ticker OBI.L. It has been listed since 6 December 2021. In the fiscal year to 31 December 2025, it reported revenue of C$2.7m and a net loss of C$29.6m. At that date it held total assets of C$14.4m and shareholders' equity of C$3.5m.

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. The company also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.

Figures and description from our data supplier, not checked against the company's own report.

More about Ondine Biomedical →

Latest on Ondine Biomedical

Our reporting

We have not reported on Ondine Biomedical yet.

Next results

3 Mar 2027

Due on 3 Mar 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Ondine Biomedical's ticker?

Ondine Biomedical trades as OBI.L on LSE, under ISIN CA68234M2058.

What was Ondine Biomedical's last closing price?

9.35p on 9 Nov 2026. The figure is in GBp and is never converted.

When does Ondine Biomedical next report results?

Results are expected on 3 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.